gdc

Web Exclusives

Leukemia
For many patients with chronic lymphocytic leukemia (CLL), treatment is personalized. This means that oncologists tailor their medication choices based on the patient’s unique CLL characteristics and medical status.
Leukemia
Targeted therapies are effective in controlling chronic lymphocytic leukemia (CLL). New research is now looking into the impact that these agents can have on autoimmune conditions.
Leukemia
A new type of immunotherapy, allogeneic cord blood–derived CAR NK-cells, could be a future option for patients with chronic lymphocytic leukemia (CLL), based on results from an early-phase clinical trial showing high response rates among patients.
Can Artificial Intelligence Help Win the Fight Against Breast Cancer?
Breast Cancer
Machines that use artificial intelligence—such as Siri and Alexa—have become part of our everyday lives. Could this technology help in the fight against breast cancer? See how human doctors stacked up against machines in one study.
Leukemia
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials.
Leukemia
When treating patients with CLL, understanding specific details about the disease helps doctors as they choose among available treatments. CLL experts believe that conducting specific blood tests before prescribing each patient’s treatment is critical. Do all doctors who treat patients with CLL also appreciate this need for testing?
Leukemia
In a large clinical trial, ibrutinib was shown to be effective in delaying disease progression in patients with early-stage, high-risk CLL who did not yet have symptoms. Researchers are now conducting clinical trials to determine the safety and efficacy of next-generation drugs and combinations in patients with early-stage, high-risk disease.
Leukemia
In the era of targeted treatments for CLL, should patients with early-stage disease be placed on therapy before they experience symptoms? Doctors continue to debate this question while waiting for clinical trial data to evolve.
Leukemia
Chronic lymphocytic leukemia (CLL) is a type of blood cancer. Some patients with CLL may not need treatment right away, whereas others require more urgent attention. How do cancer specialists decide when to start patients on therapy?
Leukemia
There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes can affect how much patients must pay out of pocket for their medications, including certain cancer drugs.
Page 4 of 15
Results 31 - 40 of 145

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country